Want to see CTOR full AI Analyst Report?
Top Page
Citius Oncology
(NASDAQ:CTOR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.62
▲(10.00% Upside)
Action:Reiterated
Date:07/29/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and increasing cash burn) and bearish technicals (trading below all major moving averages). Offsetting factors include positive corporate developments (added financing and supportive clinical/commercial updates), while valuation signals are limited due to negative earnings and no dividend data.
Positive Factors
Promising clinical efficacy and expansion potential
Durable responses and a 24% overall response rate in a heavily pretreated population indicate meaningful clinical activity for LYMPHIR combos. Planned Phase 2 expansion and translational work could broaden the label beyond CTCL, increasing addressable market and long-term commercialization optionality.
Negative Factors
Pre-revenue business model
With no product sales yet, CTOR must convert clinical outcomes into commercial uptake to generate sustainable cash flow. The company's long-term outlook depends on regulatory success, market access, and execution of launch plans—execution risks that materially affect viability over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising clinical efficacy and expansion potential
Durable responses and a 24% overall response rate in a heavily pretreated population indicate meaningful clinical activity for LYMPHIR combos. Planned Phase 2 expansion and translational work could broaden the label beyond CTCL, increasing addressable market and long-term commercialization optionality.
Read all positive factors
Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$55.07M
Dividend YieldN/A
Average Volume (3M)56.61K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume44,100
30 Day Avg. Volume56,609
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$20.82M
Citius Oncology Business Overview & Revenue Model
Company Description
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling...
How the Company Makes Money
null...
Citius Oncology Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.61M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -41.08M | -23.49M | -20.57M | -12.12M | 0.00 |
| Net Income | -42.51M | -24.76M | -21.15M | -12.70M | -10.87M |
Balance Sheet | |||||
| Total Assets | 100.70M | 100.94M | 84.37M | 47.73M | 42.69M |
| Cash, Cash Equivalents and Short-Term Investments | 2.63M | 3.92M | 112.00 | 0.00 | 0.00 |
| Total Debt | 3.80M | 3.80M | 3.80M | 0.00 | 0.00 |
| Total Liabilities | 65.43M | 56.08M | 38.23M | 22.20M | 6.42M |
| Stockholders Equity | 35.27M | 44.87M | 46.14M | 25.54M | 36.27M |
Cash Flow | |||||
| Free Cash Flow | -16.86M | -5.49M | 126.35K | -601.30K | -47.97K |
| Operating Cash Flow | -16.86M | -5.49M | 126.35K | -601.30K | -47.97K |
| Investing Cash Flow | -10.86M | -5.75M | -5.00M | -1.32M | -67.32M |
| Financing Cash Flow | 30.36M | 15.17M | 4.87M | 1.66M | 67.66M |
Citius Oncology Risk Analysis
Citius Oncology disclosed 52 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $29.99B | 35.73 | 2.26% | ― | 0.53% | -45.79% | |
63 Neutral | $6.84B | 14.87 | 7.88% | 3.72% | 6.84% | 61.67% | |
58 Neutral | $3.56B | 16.94 | 23.44% | 0.59% | -2.45% | -70.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $55.07M | -1.26 | -99.47% | ― | ― | ― | |
43 Neutral | $26.93M | -0.01 | 875.03% | 2.78% | ― | ― |
* Healthcare Sector Average
CTOR
Citius Oncology
0.66
-1.15
-63.54%
BIIB
Biogen
208.45
75.56
56.86%
GRFS
Grifols SA
8.07
-2.30
-22.20%
SRXH
SRx Health Solutions
1.37
-23.17
-94.42%
SCLX
Scilex Holding Company
6.47
-2.24
-25.72%
OGN
Organon
13.56
5.23
62.86%
Citius Oncology Corporate Events
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
Positive
Jun 1, 2026
On June 1, 2026, Citius Oncology reported Phase 1 data from an investigator-initiated study of its CTCL drug LYMPHIR in combination with pembrolizumab in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. Presented...
Business Operations and StrategyPrivate Placements and Financing
Citius Oncology Secures New Financing to Support LYMPHIR
Positive
May 6, 2026
On May 5, 2026, Citius Oncology secured up to $36.5 million in combined debt and equity-related capital to support the commercialization of LYMPHIR, its recently launched cutaneous T‑cell lymphoma therapy. The financings are aimed at funding...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.